Helix BioPharma Corp. (HBP.TO) Signs Capital Raising Agreement with Kerentech Consulting Ltd.

(TheNewswire)

May 14, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” ,FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near futurewhere today’s hard-to-treat cancers are vincible, announced todaythat it has signed an agreement with Kerentech Consulting Ltd.( “Kerentech” ), under which Kerentech will support Helix in its ongoingfundraising efforts.

Under the terms of the agreement, Kerentech will assist Helix in closing a bridge financinground of USD 13 million to advance the company’s lead therapeuticprograms and strategic priorities through 2025 and beyond. Thecollaboration reflects Helix’s commitment to accelerating efforts tosecure a stable financial platform and fast-track the development ofits pipeline candidates this year, beginning with its lead candidate,Tumor Defense Breaker™ L-DOS47.

“We’re pleased to team up with Kerentech as wedouble down on our efforts to deliver meaningful progress in tacklinghard-to-treat cancers as rapidly as possible,” said Thomas Mehrling, MD, PhD, ChiefExecutive Officer of Helix BioPharma . “We’re seeing strong engagementfrom investors and are focused on bringing this round to a timelyclose —so we can accelerate the clinical development of L-DOS47 incombination with an immune checkpoint inhibitor and push toward betteroutcomes in non-small cell lung cancer.”

About Kerentech Consulting Ltd.

Kerentech Consulting Ltd. is a global advisory firmspecializing in strategic fundraising and corporate development foremerging life sciences and healthcare companies. With deep industryexpertise and a robust investor network, Kerentech helps clientsunlock capital, accelerate growth, and navigate critical inflectionpoints with confidence. The firm provides tailored support acrossequity and non-dilutive financing, business strategy, and partnershipdevelopment, with a focus on delivering long-term value forinnovative, mission-driven teams.

About Helix BioPharma Corp.

Helix BioPharma is an oncology company that innovatesfrom strength to bring near-term solutions for today’shardest-to-treat cancers. The Company’s pipeline is led by TumorDefense Breaker™ L-DOS47, a clinical-stage antibody-enzyme conjugatedesigned to prime CEACAM6-expressing tumors for increased sensitivityto therapy and augment the effectiveness of today’s front-runninganti-cancer treatments. L-DOS47 has completed Phase Ib studies innon-small cell lung cancer (NSCLC) and shares its CEACAM6-targetingfoundation with Helix’s next-generation bi-specific antibody-drugconjugates (ADCs), currently in discovery. The Company also advancestwo pre-IND candidates: (i) LEUMUNA™, an oral immune checkpointmodulator aimed at achieving durable remission in post-transplantleukemia relapse, and (ii) GEMCEDA™, a first-in-class oralgemcitabine prodrug with bioavailability on a par with IV, designed toexpand treatment options for advanced cancers.

Helix is listed on TSX (HBP), OTC PINK (HBPCD), and FWB(HBP0). For more information, pleasevisit : https://www.helixbiopharma.com/

For more information, pleasecontact:

Helix BioPharma Corp.

Bay Adelaide Centre - North Tower

40 Temperance Street, Suite 2

Toronto, ON M5H 0B4

Tel: +1 857 208 7687

Dr. Thomas Mehrling, CEO and Director

corporate@helixbiopharma.com

Forward-Looking Statements and Risksand Uncertainties

This news release containsforward-looking statements and information (collectively,“forward-looking statements”) within the meaning of applicableCanadian securities laws. Forward-looking statements are statementsand information that are not historical facts but instead includefinancial projections and estimates, statements regarding plans,goals, objectives, intentions and expectations with respect to theCompany’s future business, operations, research and development,including the Company’s activities relating to L-DOS47, LEUMUNA™and GEMCEDA™. Forward-looking statements can further be identifiedby the use of forward-looking terminology such as “ongoing”,“estimates”, “expects”, or the negative thereof or any othervariations thereon or comparable terminology referring to futureevents or results, or that events or conditions “will”, “may”,“could”, or “should” occur or be achieved, or comparableterminology referring to future events or results.

Forward-looking statements arenecessarily based on a number of estimates and assumptions that theCompany considered appropriate and reasonable as of the date suchinformation is given, including but not limited to the assumptionsregarding the implied benefits of the transactions. Forward-lookingstatements are subject to known and unknown risks, uncertainties, andother factors, many of which are beyond the Company’s control, thatmay cause actual results, performance or achievements to be materiallydifferent from those expressed or implied by such forward-lookingstatements, including but not limited to the risk that the Company'sassumptions on which its forward-looking statements are based may notbe accurate; the ability of the Company to capitalize on the potentialbenefits of the transactions; and the risk factors disclosed in theCompany's periodic reports publicly filed and available on its SEDAR+profile at www.sedarplus.ca. No assurance can be given that any ofthe events anticipated by the forward-looking statements willtranspire or occur. There is no assurance that the proposedtransactions will be completed in accordance with its terms or at all.The forward-looking statements contained in this news release are madeas of the date of this announcement and the Company does not assumeany obligation to update any forward-looking statement or informationshould those beliefs, assumptions, opinions or expectations, or othercircumstances change, except as required by law.

_________________

Copyright (c) 2025 TheNewswire - All rights reserved.